Ignite Creation Date:
2025-12-24 @ 11:02 PM
Ignite Modification Date:
2026-01-02 @ 4:12 AM
Study NCT ID:
NCT00509769
Status:
COMPLETED
Last Update Posted:
2013-04-02
First Post:
2007-07-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Sponsor:
Genentech, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-07
Start Date Type:
None
Primary Completion Date:
2009-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-06
Completion Date Type:
ACTUAL
First Submit Date:
2007-07-27
First Submit QC Date:
None
Study First Post Date:
2007-07-31
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2013-02-22
Results First Submit QC Date:
None
Results First Post Date:
2013-04-02
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-02-22
Last Update Post Date:
2013-04-02
Last Update Post Date Type:
ESTIMATED